share_log

Brain Scientific Sees Increased First-Quarter Sales Momentum and Revenue Growth

Brain Scientific Sees Increased First-Quarter Sales Momentum and Revenue Growth

腦科學看到第一季度銷售勢頭增加和收入增長
GlobeNewswire ·  2023/02/28 23:20

A significant order from a high-tech robotics company highlights growing interest in Piezo Motion's new series of piezomotors. Additional orders for the Company's new ferrous-free (non-magnetic) high torque motor underscores its suitability in medical MRI robotics applications.

一家高科技機器人公司的重大訂單凸顯了對 Piezo Motion 新系列壓電機的興趣日益增長。該公司新型無鐵(非磁性)高扭矩馬達的額外訂單突顯了其在醫療 MRI 機器人應用中的適用性。

LAKEWOOD RANCH, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Piezo Motion, a Florida-based Brain Scientific (OTCQB:BRSFD) technology company, announces today increased demand for its new range of novel miniature rotary piezomotors (the RAS Series). The highly precise yet very affordable RAS motor is finding use in a growing range of applications including photonics, medical devices and miniature pumps. 

佛羅里達州萊克伍德牧場,2023 年 2 月 28 日(環球美通社)-- 通過投資者網絡-壓電運動,總部位於佛羅里達州的大腦科學(OTCQB:BRSFD) 科技公司,今天宣布對其新型微型旋轉壓電機(該系列的新型微型旋轉壓電機)的需求增加 RAS 系列).高精度但價格合理的 RAS 馬達可用於不斷增長的應用範圍,包括光子學、醫療設備和微型泵浦。

"We just received our largest order to date for our new miniature motor from a hi-tech company that is working in the photonics space," said Dr. Mark Broderick, president of Piezo Motion. "It really was just a matter of time before our RAS motor started to get the attention it really deserves."

Piezo Motion 總裁 Mark Broderick 博士表示:「我們剛剛從事光子學領域的高科技公司獲得了迄今為止最大的新型微型電動機訂單。「在我們的 RAS 馬達開始獲得真正值得關注之前,這只是一個時間問題。」

Another significant development with Piezo Motion is the growing interest in our new and completely ferrous-free (non-magnetic) high-torque motor. The company received an order from the University of Hawaii and is also collaborating under contract with a US-based designer of medical robotics; both these applications are applying our non-magnetic motor within the field of medical MRI where traditional motors cannot operate.

Piezo Motion 的另一個重要發展是對我們全新且完全無鐵(非磁性)高扭矩電動機的興趣日益增長。該公司收到了夏威夷大學的訂單,並與美國的醫療機器人設計師簽訂合同合作;這兩種應用都在醫療 MRI 領域應用了我們的非磁性電機,而傳統電機無法運行。

Along with these large orders, the company reported that a number of entrepreneurs and innovators are doing incredible things with Piezo Motion's innovative motors. For example, Reuben Brewer, an SRI employee, robotics-class professor at Stanford, and a home robotics lab mad scientist-type said, "I've tried out the new motor (RAS), and I love it! It has a very respectable torque, is reliable and a great price compared to alternative and bulkier traditional motors."

隨著這些大訂單,該公司報告說,許多企業家和創新者正在使用 Piezo Motion 的創新電機做出令人難以置信的事情。例如,斯坦福大學的 SRI 員工,機器人級教授 Reuben Brewer 和家庭機器人實驗室瘋狂科學家類型說:「我已經嘗試了新的電機(RAS),我喜歡它!與替代和更大的傳統電機相比,它具有非常可觀的扭矩,可靠且價格實惠。」

Piezo Motion's technologies, which are protected by 27 worldwide patents, are applicable to a vast array of diversified markets including:

Piezo Motion 的技術受到 27 項全球專利的保護,適用於廣泛的多元化市場,包括:

  • Life science
  • Medical devices
  • Robotics
  • Aerospace
  • Semiconductor
  • Optics
  • Automotive systems 
  • 生命科學
  • 醫療器械
  • 机器人
  • 航太
  • 半导体
  • 光学
  • 汽車系統

"Our piezo motors are filling a unique gap in the market. They are tiny, energy-efficient and precise, yet extremely affordable, finally allowing device manufacturers to use piezoelectric motors for large-scale manufacturing," said Hassan Kotob, chairman and CEO of Piezo Motion.

「我們的壓電電機正在填補市場上獨特的空白。Piezo Motion 董事長兼首席執行官 Hassan Kotob 表示,它們體積小巧,高效且精確,但價格實惠,最終允許設備製造商使用壓電馬達進行大規模製造。

About Piezo Motion

關於壓電運動

Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today's global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.

Piezo Motion (piezomotion.com) 是一家 Brain Scientific 公司,是精密馬達技術領域的領導者,投資數百萬美元投資於經濟實惠的壓電馬達的研發,以滿足並超越當今全球市場的需求。該公司致力於開發創新技術和運動產品,以在多種應用中增強功能。該公司與來自世界各地的初創公司,OEM,研究機構和工業公司合作,為其產品背後的遠見者提供了支持。

About Brain Scientific

關於腦科學

Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.

腦科學(腦科學)是一家擁有多項專利和 FDA 批准產品的醫療技術公司。大腦科學致力於開發新一代解決方案,以推動神經診斷和 OEM 醫療設備的未來發展。腦科學有兩個產品線,涵蓋神經病學和精確運動。NeuroCap™ 和 NeuroeEG™ 是智能神經診斷設備,可簡化管理,縮短掃描時間並降低成本。Piezo Motion 產品系列由超高效緊湊型精密電機組成,可驅動下一代醫療設備。如欲了解更多有關腦科技的企業策略、產品或投資者關係,請瀏覽腦科學網站。

Forward-Looking Statements

前瞻性陳述

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.

本新聞稿中包含的任何不描述歷史事實的陳述可能構成前瞻性陳述。前瞻性聲明可包括(但不限於)有關(i)未來經營管理的計劃和目標的聲明,包括與 EEG 產品和服務和壓電機技術的設計、開發和商業化有關的計劃或目標;(ii)每股收入(包括收益/虧損)、每股資本支出、股息或其他財務項目(包括收益/虧損);未來財務表現;(iv)壓電運動與壓電運動的成功整合並納入腦科學;及 (v) 與上述第 (i)、(ii)、(iii) 或 (iv) 點所述的任何陳述相關的假設。這種前瞻性陳述並不意味著預測或保證實際結果,績效,事件或情況,並且可能無法實現,因為它們是基於公司當前的預測,計劃,目標,信念,期望,估計和假設,並且受到許多風險和不確定性和其他影響,對其中許多公司無法控制。由於這些風險和不確定因素,某些事件和情況的實際結果和時間可能與前瞻性陳述中描述的結果和時間有很大差異。可能影響或導致前瞻性陳述不準確或導致實際結果與預期或預期結果有重大差異的因素可能包括但不限於公司無法獲得額外融資;與產品開發相關的時間和資源以及相關的現金流不足以及導致不足以及導致不足的業務;公司無法擴大其業務;政府對醫療產品的監管和醫療產品缺乏的重大監管多樣化; 在公司的原材料價格的波動; 以及未能實施公司的業務計劃或戰略.其中一些因素和其他因素在公司向 SEC 提交的文件中更詳細地識別和描述。該公司不承諾更新這些前瞻性陳述。

CONTACTS

連絡人

INVESTORS
ir@brainscientific.com

投資者
ir@brainscientific.com

MEDIA
pr@brainscientific.com

媒體
pr@brainscientific.com

Corporate Communications

企業溝通

IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
Editor@InvestorBrandNetwork.com

IBN (投資者品牌網絡)
洛杉磯, 加利福尼亞
辦公室
Editor@InvestorBrandNetwork.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論